Search company, investor...
Horizon Discovery company logo

Horizon Discovery

horizondiscovery.com

Founded Year

2007

Stage

Acq - P2P | Acquired

Total Raised

$49.6M

Valuation

$0000 

Revenue

$0000 

About Horizon Discovery

Horizon Discovery is a UK translational genomics company developing and supplying patient-relevant drug discovery and diagnostic reference standards. The company is a supplier of genetically-defined cell lines, reporter gene assay kits, genomic reference standards, and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development.On December 23rd, 2020, Horizon Discovery was acquired by PerkinElmer.

Headquarters Location

8100 Cambridge Research Park Waterbeach

Cambridge, England, CB25 9TL,

United Kingdom

+44 (0) 1223 976 000

Missing: Horizon Discovery's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Horizon Discovery's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Horizon Discovery

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Horizon Discovery is included in 2 Expert Collections, including Omics.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

B

Biopharma Tech

838 items

Horizon Discovery Patents

Horizon Discovery has filed 1 patent.

The 3 most popular patent topics include:

  • Genetics
  • Molecular biology
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/10/2017

7/26/2022

Molecular biology, Genetics, Biotechnology, DNA, Transcription factors

Grant

Application Date

2/10/2017

Grant Date

7/26/2022

Title

Related Topics

Molecular biology, Genetics, Biotechnology, DNA, Transcription factors

Status

Grant

Latest Horizon Discovery News

Global Oligonucleotide Synthesis Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts

Dec 2, 2022

The global oligonucleotide synthesis market reached a value of US$ 2.4 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 4.8 Billion by 2027, exhibiting a CAGR of 12.25% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor. Oligonucleotide synthesis is a chemical process wherein short fragments of nucleic acids are linked to each other for forming desired sequenced products. It can be customized by researchers according to the application and their requirements. It is used as primers and probes in recombinant DNA technologies to develop monoclonal antibodies. It is also utilized in biological, medical, forensic, and clinical applications for gene expression, cloning, molecular diagnostics, and genetic disease screening. Moreover, it is gaining traction in therapeutics practices for several drugs on account of the introduction of automated reactor platforms, which provide access to oligonucleotides at reasonable prices. With the increasing cases of coronavirus disease (COVID-19) and the urgency for a potential treatment, new generations of oligonucleotide drugs, including mRNA and DNA vaccines, are currently under development. Apart from this, the growing incidences of cancer and other chronic illnesses have resulted in the rising demand for novel diagnostics, which is influencing the need for oligonucleotide synthesis to help develop effective therapies and diagnostic techniques. The increasing geriatric population and demand for personalized medicines are also bolstering the market growth. Additionally, with advances in purification and quality control technologies, the overall cost of oligonucleotide techniques can be decreased while substantially increasing quality and yield. This is promoting the application of oligonucleotide synthesis in a range of available modifications. Apart from this, several oligonucleotide-based therapies are in different stages of clinical trials. This is anticipated to propel the demand for oligonucleotide synthesis to treat viral infections, rare genetic disorders, and neuromuscular conditions. Report Attribute Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Biolegio B.V., Bio-Synthesis Inc, Eurofins Genomics, GenScript, Horizon Discovery Ltd, Integrated DNA Technologies Inc (Danaher Corporation), Kaneka Eurogentec S.A. (Kaneka Corporation), LGC Limited, Nitto Denko Avecia Inc (Nitto Denko Corporation) and Thermo Fisher Scientific Inc. Key Questions Answered in This Report: How has the global oligonucleotide synthesis market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global oligonucleotide synthesis market? What are the key regional markets? What is the breakup of the market based on the product? What is the breakup of the market based on the application? What is the breakup of the market based on the end use? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global oligonucleotide synthesis market and who are the key players? What is the degree of competition in the industry? Key Topics Covered:

Horizon Discovery Frequently Asked Questions (FAQ)

  • When was Horizon Discovery founded?

    Horizon Discovery was founded in 2007.

  • Where is Horizon Discovery's headquarters?

    Horizon Discovery's headquarters is located at 8100 Cambridge Research Park, Cambridge.

  • What is Horizon Discovery's latest funding round?

    Horizon Discovery's latest funding round is Acq - P2P.

  • How much did Horizon Discovery raise?

    Horizon Discovery raised a total of $49.6M.

  • Who are the investors of Horizon Discovery?

    Investors of Horizon Discovery include PerkinElmer, Molten Ventures, MVM Partners, Roche Venture Fund, Peter Collins and 12 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.